Topic suspended
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
28 February 2020 Suspended, Topic suspended
28 February 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of ublituximab in combination with ibrutinib for previously treated high-risk chronic lymphocytic leukaemia. The company have advised that they will not be pursuing a Marketing Authorisation Application for ublituximab in combination with ibrutinib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance